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The major histocompatibility complex (MHC) is the most gene-dense and polymorphic 
region in the human genome with strong associations to many autoimmune disorders, 
including rheumatoid arthritis (RA). However, even the genetic association between MHC 
and RA was known more than 40 years ago, we still have not fully explained the functional 
roles of the MHC genes and identified the underlying specific polymorphisms. This thesis 
describes some of our research aimed for a better understanding of this topic, which can 
largely be divided into three parts as follows. 
First, we made use of a panel of MHC class II (MHC-II) congenic strains to evaluate the 
functional roles of MHC-II polymorphisms in arthritis. By performing an extensive genetic 
and functional analysis, we showed that MHC-II RT1-B (the rat orthologs of HLA-DQ) 
determines the onset and severity of experimental arthritis, possibly due to the amino acid 
variations in the P1 pocket of RT1-B. In addition, we showed that natural allelic variants in 
Tap2, another gene in the MHC-II region, regulates the thymic selection of CD8+ T cells.  
Second, in order to investigate whether other MHC genes also contribute to arthritis 
susceptibility, we assessed arthritis development in congenic strains mapped to other parts 
of the MHC region. We identified a second arthritis-regulatory QTL in the MHC class III 
region, that regulates not only the onset and severity, but also chronicity of arthritis. We 
subsequently mapped this effect to a conserved, 33-kb large haplotype Ltab-Ncr3 
comprising five polymorphic genes. Interestingly, unlike other positionally-identified 
arthritis genes in rats, Ltab-Ncr3 regulates only adjuvant arthritis models but not 
autoimmunity triggered by specific tissue antigens, such as type II collagen. Furthermore, 
we found that gene expression and alternative splicing of the Ltab-Ncr3 genes correlate 
remarkably with arthritis severity and some of the gene expression differences were 
reproduced in a cohort of RA patients and healthy controls.  
Third, the MHC-II gene expression is regulated by class II transactivator (CIITA or C2TA), 
and in humans, genetic variation in CIITA has been associated with differential expression 
of MHC-II and susceptibility to autoimmune diseases. Using a congenic mouse strain with 
an allelic variant in the type I promoter of C2ta, we demonstrate that whereas genetic 
polymorphisms in C2ta promoter result in differential MHC-II expression and antigen 
presentation, these do not necessarily have a strong impact on autoimmune diseases such as 
arthritis.  
In summary, these studies demonstrate how the congenic approach remains powerful to 
conclusively identify and characterise genes regulating a complex disease like arthritis. 
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1. RHEUMATOID ARTHRITIS 
Rheumatoid Arthritis (RA) is a chronic, autoimmune disorder characterised by the 
destruction of synovial joints, leading to joint deformity and severe disability. It is 
estimated to affect around 0.5-1.0% of adults in the developed world with a higher 
prevalence in women than men, and at older ages (1). Major symptoms of RA are pain, 
stiffness and swelling of multiple peripheral joints. Uncontrolled active RA not only leads 
to reduced quality of life, but also a shorter life expectancy because of cardiovascular and 
other comorbidities. RA also leads to enormous direct and indirect costs to society. For 
instance, around one-quarter of individuals with RA, if untreated, will not be able to work 
within two to three years of clinical diagnosis (2). Both genetic and environmental factors 
contribute to the development of the disease. So far more than 100 risk loci, as well as 
several environmental risk factors have been linked to RA (3, 4). Despite the enormous 
progress made in understanding this complex disease, especially over the past twenty or so 
years, there is currently no preventive treatment or cure for RA. Thus, gaining a better 
knowledge into the aetiology of RA is essential for developing effective therapies to cure 
this disease. Animal models have proven to be important to study the cause, development 
and treatment of the disease.  
1.1 Autoimmunity 
Based on our current epidemiologic, genetic and clinical findings, RA pathogenic 
development can be largely divided into three stages, autoimmune priming, tissue attack 
and chronic inflammation (5). In the first stage, environmental factors seem to trigger 
innate immunity and induce adaptive immune responses in genetic-susceptible individuals, 
leading to autoantibody production and disease development at a later stage. During this 
stage, autoantibodies, such as rheumatoid factors (RFs) (6), anti–citrullinated protein 
antibodies (ACPAs) (7) can be detected in serum. Epidemiological data suggested that 
environmental factors, rather than MHC-II genetic association, drives the early production 
of autoantibodies suggesting a role of innate immune system at this stage (8). Genetic 
factors such as MHC-II alleles may have a more important role in determining the 
susceptibility of developing RA (8, 9). It is not exactly known which adjuvants triggers 
disease onset in genetically-susceptible individuals but mineral oil exposure and cigarette 
smoking have been associated with ACPA and RF responses in RA (9–11). The second 
stage is the clinical onset marked by a joint-specific inflammatory reaction. An increased 
number of activated CD8+ T cells and CD19+ B cells was found in inguinal lymph nodes 
(12) and ACPAs have been shown to be able to stimulate osteoclastogenesis causing 
structural bone damage even before clinical onset (13). However, whether autoreactive T 
and B cells, and autoantibodies such as RFs and ACPAs are arthritogenic or regulatory in 
pre-arthritis phase is currently not clear. The third stage is when the disease develops into 
an active, chronic relapsing inflammation leading to tissue destruction and bone deformity. 
The wide range of effective biological treatments indicates the heterogeneity of the disease. 
For example, chronic RA can be treated by neutralising TNF and IL-6 (which is largely 
produced by macrophages), by blocking T-cell costimulation or by anti-CD20 treatment as 
discussed further in section 1.7. 
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1.2. Epidemiology 
The incidence of RA increases with age. In Sweden, the mean age of onset is around 50-60 
years old with a female dominance (7). The lifetime risk of developing RA among adults is 
estimated to be around 2.7% for women and 1.5% for men. Globally, there is regional 
variation in the prevalence of RA (14, 15). The native American-Indian populations have 
the highest recorded prevalence of RA, 5.3% for Pima Indians and 6.8% for Chippewa 
Indians. In contrast, lower prevalence has been found in Africa and Asia with a prevalence 
of 0.2-0.3% reported in China and Japan (14, 15). A prevalence of 0.5-1.1% has been found 
in Northern Europeans and North Americans; and 0.3-0.7% in Southern Europeans. This 
regional variance in RA prevalence could be due to both genetic and environmental factors.  
1.3. Diagnosis Criteria 
The diagnosis of RA depends on clinical features, laboratory tests and/or radiological 
testing. One of the most widely accepted criteria for defining RA is the American College 
of Rheumatology (ACR) 1987 criteria (16) (Table 1), which is designed to identify patients 
with established RA and exclude those with other rheumatological diagnoses (16). 
However, the ACR 1987 criteria have been criticized for their lack of sensitivity to identify 
patients who could benefit from early effective intervention. Therefore, ACR and European 
League Against Rheumatism (EULAR) developed the 2010 ACR/EULAR classification 
criteria for RA with the main goal of facilitating the identification of individuals at the 
earlier stages of the disease (17) (Table 2). In addition to RF already included in the 1987 
ACR criteria, indicators of ongoing inflammation including ACPA, erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP), are included in the 2010 
classification criteria. 
Table 1: The 1987 ACR criteria for the classification of RA (16) 
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Classification criteria: A patient shall be said to have RA when four or more of the seven 
criteria are fulfilled. Criteria I - IV must have been present for at least 6 weeks. PIP: 
"proximal interphalangeal joints, MCP: metacarpophalangeal joints, MTP: 
metatarsophalangeal joints. 
Table 2: The 2010 ACR/EULAR criteria for the classification of RA (17) 
 
Classification criteria: total score of criteria I – IV and a score of ≥ 6/10 is needed for 
classification of a patient as having definite RA. 
1.4 Autoantibodies 
RA patients have autoantibodies against a variety of potential autoantigens, including 
fibrinogen, vimentin, collagen and α-enolase, that display varying sensitivity and specificity 
in RA. One of the 1987 ACR criteria and the 2010 ACR/EULAR criteria for the 
classification of RA is serology (16, 17). It is known that autoantibodies, such as RF or 
ACPA, can be detected in serum many years before the clinical onset (7, 18, 19), although 
the exact time point they appear remain to be clarified. The response to treatment has also 
been associated with the presence of RF and ACPA (20).  
RF is an autoantibody against the Fc portion of IgG antibodies. RF is primarily associated 
with RA, present in around 75% of patients with RA (21) and can be detected many years 
before RA onset (6, 7). The presence of RF in patients with RA has also been linked to 
severity and increased mortality (22, 23). However, the specificity of RF is low and can be 
detected in patients with other autoimmune disorders and infectious disease (24), as well as 
3-5% of healthy population. ACPAs, on the other hand, are more specific for distinguishing 
RA from other rheumatic diseases and are more predictive for future development of RA 
(25, 26), and are therefore a better diagnostic and predictive marker of RA. ACPAs were 
first discovered in 1964 as anti-perinuclear factor (APF) directed to keratohyaline graunules 
in the cytoplasm of buccal mucosal cells (27). APF antibodies were found to be highly 
sensitive (present in 49-91% of RA patients) and highly specific (73-99%) (28). It was later 
found that the recognition of antigen depended on the process of citrullination, which 
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converts arginine to citrulline by the enzyme peptidylarginine deiminase (29). Based on 
these findings, commercial assays have been developed to test for the presence of 
autoantibodies to cyclic citrullinated proteins (CCP).  
1.5 Genetic factors 
RA is a genetic disease and this is evident from the concordance rate of 15% among 
monozygotic twins (30, 31). The heritability of RA is estimated to be 40-60% (8, 30, 32). 
ACPA-positive and ACPA-negative RA have been described as two genetically different 
subsets, since they differ in susceptibility loci, the effect size, as well as the strength of 
genetic association (33).  
Among all the RA risk loci identified, the human leukocyte antigen (HLA), encoded by the 
major histocompatibility complex (MHC), exhibits the strongest association to RA. The 
HLA region was linked to RA half a century ago (34), long before the GWAS was 
performed. In humans, the MHC locus spans around 4 Mb containing over 200 genes; 
around half of these genes have immune-related functions. The MHC region is 
characterised by high gene density, extreme polymorphism and strong linkage 
disequilibrium (LD), which has hampered the identification of variants driving the MHC 
disease association. In fact, the MHC region has been described as the most gene-dense in 
the human genome (35). The MHC was first identified to be associated with RA when a 
higher prevalence of HLA-DR4 was found in mixed lymphocyte cultures of RA patients 
(34). The ‘shared-epitope’ hypothesis later described a conserved amino acid sequence 
motif comprising residues 70-74 in the third hypervariable region in the HLA-DRB1 chain 
that is associated with RA (36). The shared epitope (SE) association was recently refined to 
six different amino acids in HLA-DRB1, HLA-A, HLA-B, and HLA-DPB1 (3, 4).  
Association with several other non-HLA genes were discovered after MHC association, 
including PTPN22 (protein tyrosine phosphatase 22) (37) and CTLA4 (cytotoxic T-
lymphocyte protein 4) (38), PADI4 (protein-arginine deiminase type 4) (39), TRAF1 
(tumour necrosis factor receptor-associated factor 1) (40) and FCRL3 (Fc receptor-like 
protein 3) (41). Most other risk loci we know today are identified in GWAS and they confer 
relatively modest effects (OR < 1.2). It is important to note that despite enormous progress 
made over the past 20 years in identification of risk loci, all the risk loci we have identified 
so far only explain a small fraction of the genetic variance of RA. HLA explains the ~13% 
of the genetic variance; and other non-MHC loci explain another 5% (3, 4) meaning a 
significant proportion of genetic variance of RA remains unexplained. There are multiple 
reasons that we have not been able to identify this ‘missing heritability’. These include 
genetic heterogeneity, the low penetrance of disease alleles, strong LD with nearby genes, 
as well as gene-gene and gene-environmental interactions taking place which hamper the 
identification of disease-driving genetic factors (42).  
1.6 Environmental factors 
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While the exact pathogenic mechanisms triggering RA is unclear, different environmental 
triggers have been suggested including smoking, exposure to silica and oil, alcohol, diet, 
oral bacteria, gut microbiota, and socioeconomic status, as discussed below.  
Smoking is by far shown to be the strongest risk factor for the development of RA and 
consistently replicated in different populations (43–48). Any type of smoking (ever, current 
and past) increases risk for developing RA (49). The risk of developing RA is dose-
dependent and increases by 26% for 1-10 pack-years, 94% for 20-30 pack-years and 107% 
for >40 pack-years (50). This risk was significantly higher among RF-positive RA cases 
(49, 50). The effect of smoking on RA is long-lasting and risk remains elevated 20 years or 
more after cessation (43, 51), although one study found that such risk decreased over time 
since cessation (43). Cigarette contains more than 4000 chemical compounds (including 
over 50 known carcinogens), which may have an adjuvant effect as discussed later. 
The association of the risk of developing RA with cigarette smoking has led to further 
studies into any RA association in respiratory exposure to air pollutants, with some 
evidence suggesting that exposure to air pollution could increase risk of RA (52, 53). 
Occupational exposure to silica through exposure to stone dust, rock drilling or stone 
crushing was also associated with an increased risk of developing RA in Caucasian and 
Asian populations (54, 55). An increased risk of developing RA was also found in workers 
exposed to mineral oils (10). It is known that administration of adjuvant induces an erosive 
polyarthritis in certain rat strains (56, 57). Whether similar mechanisms also operate in 
humans is an open question and animal models could be useful in understanding how 
adjuvants may trigger autoimmunity in humans.  
Interestingly, a significant inverse association was found between low to moderate alcohol 
consumption and RA risk for both men and women (58–61). Compared with non-drinkers, 
low to moderate alcohol consumptions reduces risk for developing RA in a manner that 
appears to be dose-dependent, time dependent and sex dependent. However, as in most 
epidemiological studies, such studies can be vulnerable to influences from confounding 
factors, for instance, underestimation or underreporting in alcohol consumptions by the 
participants.  
Dietary habits have been studied for association with risk of developing RA. For instance, 
fatty fish consumption has been associated with disease protection (62–65). Greater intake 
of fruits and (cruciferous) vegetables, as well as supplemental vitamins, and lower intake of 
red meat could reduce RA risk (66–68). The traditional Mediterranean diet featured with 
high consumption of fruit, vegetables, fish, olive oil, less red meat and moderate alcohol 
has been also associated with protective effects in some diseases (69) but not RA (70). 
However, these data should also be taken with cautions since not all the data could be 
reproduced and some are inconclusive due to low number of RA patients (65, 71–73).  
Higher disease prevalence in women suggests that hormones could play a role in arthritis 
development. This is consistent with the findings of reduced disease onset during 
pregnancy and increased risk of developing RA postpartum (74). RA activity was also 
found to reduce during pregnancy and ‘relapse’ after delivery (75, 76). Oral contraceptive 
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use protects patients with definite RA from progression from mild to severe disease (77, 78) 
and hormone replacement therapy brings improvement in inflammation (79). Similar 
protective effect of female sex hormone was shown in both collagen-induced arthritis (CIA) 
and experimental autoimmune encephalomyelitis (EAE) in rodents (80–82).  
In 1982, Snyderman and McCarty first proposed a correlation between RA and adult 
periodontitis. Both diseases are characterised by self-sustaining inflammation around bone 
and subsequent bone erosion. Patients with long-standing active RA are more likely to 
develop periodontal disease, and vice versa (83–85). Elevated level of oral anaerobic 
bacterial antibodies could be found in the serum and synovial fluid of patients with RA 
(86–88). It is hypothesised that one of the oral pathogens, Porphyromonas gingivalis, 
expresses a unique microbial enzyme, peptidylarginine deiminase (PAD), that citrullinates 
proteins, including fibrinogen and α-enolase, which are major potential autoantigens in RA 
and lead to intraarticular inflammation (84). This hypothesis is supported by an increase in 
anti-P. gingivalis antibody levels in RA patients (89, 90), which developed years before 
onset of symptoms (91). Presence of periodontal bacteria in synovial joints has been 
associated with an exacerbated CIA in mice (92). Furthermore, comparative studies 
conducted on faecal samples from patients with RA found changes in microbial species, 
diversity and abundance compared with controls (93–96) and altered composition of human 
intestinal microbiota has been suggested to contribute to arthritis development (97). While 
the mechanistic basis of etiological link between RA and bacteria is not completely 
understood, current data suggest that they may play a role in the regulation of autoimmune 
arthritis.  
1.7 Treatment 
The main goal of RA treatment is to stop inflammation, relieve symptoms, prevent joint 
damage, improve mobility and reduce long-term implications. Lessons from multiple 
clinical trials in treating early RA patients has led to the current recommendations that 
treatment should aim at the early stage of the disease course with intensive intervention to 
target remission.  
The current first line of treatment is disease-modifying anti-rheumatic drugs (DMARDs), 
used either alone or in combination with other drugs. Among the different DMARDs 
available, methotrexate (MTX) is well-known for its long-term safety and clinical efficacy 
and is recommended by EULAR as first line treatment for patients with active RA (98). 
Other frequently used DMARDs include sulfasalazine, hydroxychloroquine, and 
leflunomide. Less common medications are gold salts, azathioprine, and cyclosporine.  
With the introduction of biological agents such as tumour necrosis factor (TNF) inhibitors 
(inflixmab, etanercept, adalimumab, certolizumab and golimumab), anti-CD20 (rituximab), 
CTLA-4Ig (abatacept), anti-IL-6R (tocilizumab) and anti-IL-1RA (anakinra), there has 
been both significant reduction in disease activity and improvement in quality of life in RA 
patients who receive treatment. In particular, many studies demonstrated that RA patients 
benefited from TNF inhibition treatment with reduced disease activity (99). In 2015, the 
ACR issued recommendations on how patients not responding to DMARDs should be 
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treated with a TNF inhibitor alone or in combination with other DMARDs (100). There 
have been reports that etanercept treatment led to higher incidence of serious infections and 
malignancies although these have not been proven (101, 102). 
For patients not responding to MTX or other synthetic DMARDs, Tocilizumab, which is a 
humanised monoclonal antibody against IL-6 receptor, has proven to be effective (103, 
104), and can be used alone or in combination of MTX or other sDMARDs (105–107). 
Abatacept is a fusion protein composed of cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) and the Fc portion of IgG1. CTLA-4Ig binds to CD80 and CD86 on APCs, 
blocks CD28 engagement and thus prevents T-cell activation (108). Early RA patients 
treated with Abatacept and MTX achieved better clinical outcomes than patients treated 
with MTX alone (109, 110). Rituximab is a chimeric monoclonal antibody targeting CD20, 
a protein expressed on B cells. It acts by depleting B cells and is used in patients not 
responding to other biologics. When used with MTX, it leads to significantly less synovitis 
and reduced erosion and cartilage loss for responding patients (111, 112).  
Nevertheless, almost 20-50% of patients do not adequately respond or have to discontinue 
the use of conventional and biological DMARDs due to intolerance or other adverse events, 
prompting the development of several other new drugs (113). One of them is Tofacitinib, 
which acts by inhibiting the enzyme janus kinase 1 (JAK1) and JAK3 in the intracellular 
signal transduction of many cytokines. Other drugs, such as Peficitinib and Decernotinib, 
bind to different members of the tyrosine kinase family. Tabalumab is an antibody that 
neutralises both soluble and membrane-bound B-cell activating factor (BAFF). Atacicept is 
a recombinant fusion protein that neutralises the activity of APRIL and BLyS (B 
lymphocyte stimulator). Brodalumab (IL-17 receptor), Denosumab (RANKL) and 
Mavrilimumab (GM-CSF) are other antibodies under development. 
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2. ANIMAL MODELS OF RHEUMATOID ARTHRITIS 
Animal models for RA are essential not only to advance our understanding of the 
pathogenesis of RA, but also to develop treatments for a disease that is still affecting 
millions of people across the world.  
Firstly, animal models are important to improve our understanding of genetic contributing 
factors of RA. As previously mentioned, the >100 risk loci so far identified in fact account 
for only a modest fraction of the genetic variance associated with the disease (3, 42); and 
for most of these loci, very little is known about their pathogenic roles. Human genetic 
studies are restrained by factors such as the genetic heterogeneity, strong LD with nearby 
genes, small effect size of risk loci, as well as the possibility of gene-gene and gene-
environment interactions involved in the regulation of this complex disease. Animal models 
of RA overcome some of these limitations and are therefore attractive alternative 
approaches to human genetic studies to identify causative genes and to understand the 
underlying pathogenic mechanisms. For instance, the possibility to perform selective 
interbreeding of inbred lines followed by disease phenotyping of the offsprings, allows the 
identification of quantitative trait loci (QTLs) that regulate arthritis. A quantitative trait 
locus is defined as a chromosomal region linked to a variation in a phenotype (which can be 
a disease phenotype). The possibility to isolate the QTL in the form of congenic fragments 
and subsequent minimizing the size of the congenic fragment allows for positionally 
cloning and deep analysis of the gene(s) that regulates the disease trait. This strategy has so 
far proven to be successful to identify and characterise novel disease genes as will be 
discussed later. Secondly, animal models are optimal to study the environmental influence 
on RA, including smoking, alcohol, diet, and bacterial infections. In a laboratory setting, 
such factors can be carefully studied in a controlled way. Lastly, animal models are needed 
to firstly develop better drugs for the treatment of RA and for testing both their 
effectiveness and safety. Current European legislations require toxicity tests of any drugs in 
at least two mammalian species before being licensed for human use.  
2.1. Rat Models of arthritis 
In order to use animal models to improve our understanding of both genetic and 
environmental causes of RA, as well as to develop effective treatments for RA, well-
characterised animal models that reflect the complex nature of the disease are necessary. 
Since the work presented in this thesis is mostly based on rat congenic strains, rat models of 
RA will be the main focus of this discussion. In rats, there are mainly two categories of 
induced arthritis models. The first category is based on disease induction by cartilage-
derived proteins, as exemplified by collagen-induced arthritis (CIA) (114). The second 
category is based on disease induction by adjuvants alone, as exemplified by pristane-
induced arthritis (PIA) (115, 116) and oil-induced arthritis (117).  
2.1.1 Collagen-induced arthritis (CIA) 
CIA is one of the most commonly used models of RA in both rats and mice. Different 
cartilage derived proteins, including type II collagen (CII) (114), type XI collagen (CXI) 
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(118), and cartilage oligometric matrix protein (COMP) (119) can be used to induce 
arthritis in rats. CIA is typically induced by intradermal injection of native autologous rat 
CII, emulsified in incomplete Freund’s adjuvant (IFA) at the base of the tail (120). As 
opposed to CIA in mice, no mycobacterial addition or booster injection is needed in rat 
CIA. The disease course in rats is more rapid than in mice. The typical onset is around 12 to 
14 days after immunisation when rats of the DA strain start to develop polyarthritis. The 
disease then enters into a phase of remission before a chronic relapsing phase (121). Both B 
cells reactive towards native CII epitopes as well as autoreactive T cells induced by 
immunisation with autologous CII are important for the development of CIA (121, 122). 
The adoptive transfer of CIA by CII-reactive T cells is not as effective as in arthritis 
induced by adjuvants such as pristane or IFA (123, 124), suggesting the dependency on 
both B cells and T cells in CIA in rats. One advantage of CIA over mycobacterial adjuvant-
induced arthritis (Mbt-AIA) (section 2.1.5) is that the former is driven by autoimmune 
response to a defined connective tissue component rather than a bacterial arthritogen. CIA 
shares many clinical and subclinical features of human RA, including the dependency on 
both MHC and non-MHC genes, production of anti-collagen antibodies, an inflammatory 
process primarily directed to peripheral joints and a chronic disease course (125–128).  
2.1.2 Pristane-induced arthritis (PIA) 
PIA is another commonly used rat model of RA. PIA is induced by an intradermal injection 
of pristane at the base of the tail, leading to a chronic relapsing disease course (115, 116). 
Pristane (2, 6, 10, 14-tetramethylpentadecane) is a saturated hydrocarbon with 15 carbons 
on its backbone and four methyl groups at position 2, 6, 10 and 14. Pristane is a natural 
component of chlorophyll and is therefore normally eaten and absorbed by animals. Thus 
PIA, unlike CIA, is independent of exogenous antigens and it is interesting that a single 
injection of this ‘self’ component in susceptible rat strain can lead to chronic inflammatory 
disease. The subcutaneous or intradermal induction of arthritis by pristane is unique for the 
rat, since a similar injection does not induce arthritis in the mouse. However, it should be 
noted that high doses of pristane, if injected intraperitoneally, induces severe inflammatory 
disease course in mice, although the symptoms differ from PIA in rats and does not mimic 
RA (129). 
PIA usually starts 10 days after immunisation and peaks at 20 days. The inflammation then 
gradually disappears before the relapsing chronic phase with new joint inflammation and 
cartilage erosion and deformity begins. PIA shares many clinical and subclinical features 
with RA, such as edema, infiltration of mononuclear and polymorphonuclear cells into the 
joint, pannus formation, and bone and cartilage destruction. Although the exact pathogenic 
mechanism of PIA is not clear, PIA is known to be αβ T-cell dependent (117) and can be 
adoptively transferred by activated CD4+ T cells (130). There is however no evidence that 
B cells or antibodies play any pathological role in PIA (123). RF, α1-acid glycoprotein 
(AGP), cartilage oligomeric matrix protein (COMP) and the proinflammatory cytokine IL-6 
can be detected in rats with PIA. Similar to RA and CIA, PIA is regulated by both MHC 
and non-MHC genes (115, 116, 131). 
2.1.3 Oil-induced arthritis (OIA) 
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The Incomplete Freund’s adjuvant (IFA) has often been used to enhance immune response 
to antigens in different autoimmune disease induction protocols such as CIA. It was later 
unexpectedly discovered that IFA alone can induce arthritis in rats of DA strain (57, 117). 
Unlike pristane, which is a well-defined alkane molecule, IFA is a poorly defined mixture 
consisting of many hydrocarbon molecules of different molecular weights (132). In contrast 
to PIA, which is a chronic, relapsing disease model, OIA induces transient inflammation 
that usually starts 10 days after immunisation and lasts about 3 to 5 weeks (117). Other than 
these differences, OIA is very similar to PIA and leads to inflammatory, symmetrical and 
destructive polyarthritis (57). Histologic examination of the affected paws shows the typical 
features of inflammatory arthritis, including infiltration of inflammatory cells, synoviocyte 
hyperplasia, pannus formation, and bone and cartilage destruction. OIA depends on the 
polyclonal activation of T cells and can be adoptively transferred by activated T cells (123). 
Similar to RA in humans, OIA is regulated by both MHC and non-MHC genes (133). 
2.1.4 Arthritis induced by other hydrocarbons 
Hydrocarbon molecules other than pristane are also known to induce arthritis. Alkanes with 
15 carbons or more induce arthritis; whereas shorter alkanes do not (134–136). In addition 
to the length of the hydrocarbon backbone, saturation of the hydrocarbon molecule, the 
presence of the halogen atom(s) and the presence of branched group(s) are known to affect 
the arthritogenicity of the hydrocarbon (135, 136). Among all the hydrocarbon molecules, 
squalene (SIA), and to a lesser extent hexadecane (HXIA) and heptadecane (HPIA), have 
been used to study arthritis in rats. Squalene is a cholesterol precursor and one single 
intradermal injection can induce joint-specific inflammation in the arthritis-susceptible rat 
strain DA (137, 138). Squalene-induced arthritis is T cell dependent and is regulated by 
both MHC and non-MHC genes (133).  
2.1.5. Mycobacterial adjuvant-induced arthritis (Mbt-AIA) 
Mbt-AIA is induced by an intradermal injection of heat-killed mycobacteria such as 
Mycobacterium butyricum or Mycobacterium tuberculosis in incomplete Freund’s adjuvant. 
Mbt-AIA is monophasic and aggressive, and leads to severe systemic manifestations 
including splenomegaly and hepatomegaly. Although the pathogenic mechanism of Mbt-
AIA is not clear, the heat shock protein 65 (HSP65)-derived peptide from mycobacteria is 
thought to be one of the immunogens (139). Similar to RA and other arthritis disease 
models, Mbt-AIA is regulated by both MHC and non-MHC genes (140). 
2.1.6. Streptococcal cell-wall induced arthritis (SCWIA) 
Components of the streptococcal cell wall have also been used to induce arthritis in rats 
(141). Arthritis is induced by an intraperitoneal injection of a suspension of group A 
streptococcal cell-wall fragments (141). The clinical disease is characterised by an acute 
inflammation in the distal joints, detected between days 1 and 4, and a chronic phase 
occuring approximately 3 weeks after immunisation with pannus formation, cartilage 
degradation, bone erosions and T cell infiltration (142). Administration of streptococcal 
cell-wall components into athymic inbred Lewis rats results in acute arthritis but not 
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chronic arthritis, suggesting that the acute phase of SCWIA is T cell independent whereas 
the chronic phase is T cell dependent (143). SCWIA mimics various clinical features of 
RA, including inflammation in peripheral joints, synovial pannus formation and synovial 
fibroblast proliferation.  
2.2. Disease gene identification 
The availability of rat models of arthritis with stable and reducible phenotypes has 
facilitated the genetic studies of arthritis. Different genome-wide strategies have been used 
in the past 20 or so years to map arthritis-associated loci, including F2 intercross, F1 
backcross, advanced intercross lines (AILs) and heterogeneous stocks (HSs) (Figure 1). 
Initially, genetic linkage analysis is performed to identify QTLs that regulate different 
arthritis traits, such as disease onset, severity and antibody production (126, 131, 133, 140, 
144, 145). The arthritis-regulating effect of the QTL can then be reproduced in a congenic 
strain (131, 145, 146). Once the disease phenotype is reproduced in a congenic strain, 
smaller subcongenic strains that still retain the disease phenotype can be generated to 
narrow down the arthritis-associated loci (147–150). The aim is to generate a congenic 
fragment comprising the minimum number of genes, so that it is possible to positionally 
identify the underlying causative gene(s) regulating the disease phenotype, and to 
characterise the pathological roles of these gene(s) (Figure 1).  
 
Figure 1: Strategy for positional identification of genes. 
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2.2.1 Arthritis-regulating QTL mapping: linkage analysis 
The first stage in arthritis gene identification is genetic linkage analysis to map arthritis-
regulating QTLs. The aim is to locate chromosomal regions associated with the regulation 
of arthritis phenotypes. The basis of the QTL mapping is that each animal in the linkage 
analysis has a unique genotype due to recombination events occurring during meiosis. 
Therefore, each animal needs to be genotyped using genetic markers that spread along the 
chromosomes in order to detect their parental origin. In addition, each animal is also 
evaluated for phenotypes of interest (which can be a disease trait). Linkage analysis is then 
performed to construct a genetic linkage map to detect loci linked to the phenotype and a 
measurement of the probability that loci are linked is calculated as the logarithm of the odds 
(LOD) score.  
There are different methods of QTL mapping. The first method is to perform an F2 
intercross between F1 hybrids of the two strains. The offsprings can then be used in genetic 
linkage analysis to identify arthritis-associated QTLs. The second method involves 
backcrossing of the F1 hybrids with one of the two parental inbred strains and the 
offsprings are used for linkage analysis. An F2 intercross has the advantage of giving more 
information concerning recessive alleles inherited from either of the two parental strains 
and also allows higher resolution mapping of genes with additive inheritance. A backcross 
analysis is more statistically powerful but identifies less QTLs (151).  
Using PIA as an example, both F2 intercross and F1 backcross were successfully applied to 
identify QTLs in different chromosomes regulating different arthritis traits (131, 152). For 
example, an F2 intercross between arthritis-susceptible DA and arthritis-resistant E3 
showed that Pia2 and Pia3 (loci on chromosome 4 and 6) regulate arthritis onset, Pia4 
(chromosome 12) regulates arthritis severity and joint erosion, and Pia5 and Pia6 
(chromosome 4 and 14) are associated with arthritis chronicity (152). A later backcross 
analysis reproduced some of these findings and identified new QTLs Pia10, Pia12, Pia13, 
Pia14, and Pia15 on chromosomes 10, 6, 7, 8, and 18, respectively (131). Similar genome-
wide linkage analyses were used in CIA (126, 127) and Mbt-AIA (140). Most disease loci 
associate with both types of arthritis models, adjuvant-based (usually pristane and/or IFA) 
and antigen-based (usually type II collagen) (126, 145); however a few loci are implicated 
in only certain arthritis models. For example, Cia4 regulates PIA and OIA but not CIA, 
whereas Cia6 regulates OIA but not PIA and CIA (145), indicating specificity in the 
pathways in which some of these QTLs may operate.  
In addition to F2 intercross and F1 backcross, another genome-wide QTL mapping strategy 
is HS. The rat HS is generated by intercrossing 8 inbred progenitor strains (ACI/N, 
BN/SsN, BUF/N, F344/N, M520/N, MR/N, WKY/N and WN/N) for ~60 generations (153) 
and has been used to map QTLs regulating different phenotypic traits (154). However, this 
strategy cannot be used to study arthritis QTLs because the inbred progenitor strains used to 
generate HS are resistant to arthritis (Tuncel and Holmdahl, unpublished). Similar 
limitations also occurred in HS mice (known as the Northport Stock) since the original 
inbred mouse strains used in the HS (namely A/J, AKR/J, BALB/CJ, LP/J, CBA/2J, 
C3H/HeJ, C57BL/6J and DBA/2J) lack the MHC class II H2q haplotype for presentation of 
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the immunodominant peptide of type II collagen (155). This was shown when the 
immunisation of the HS mice with CII induced almost no arthritis (156). To resolve this 
problem, the HS mice were crossed with an inbred strain, C57BL/10.Q, which has the 
arthritis-permissive H2q haplotype. These HS mice backcrossed to C57BL/10.Q were then 
successfully used to identify loci regulating different arthritis traits, such as disease onset, 
severity, incidence and antibody production (155, 157).  
Another QTL-mapping approach is advanced intercross lines (AILs), which are lines 
generated by first crossing two inbred strains (for example, DA and PVG) to produce an F1 
generation and then randomly intercrossing the progeny for many generations. Through 
random and repeated intercrossing, the rats accumulate new recombinations in every 
generation. In one group, rat AILs were used to study myelin oligodendrocyte glycoprotein-
induced experimental autoimmune encephalomyelitis (MOG-EAE), a chronic relapsing 
model that mimics multiple sclerosis in rats (158–161). This AIL was generated by crossing 
EAE-susceptible DA and EAE-resistant PVG.1AV1 rat strains and was successfully used to 
identify and fine-map EAE-regulating QTLs (158–161). Another AIL panel GKxF344 was 
used to identify the locus regulating rheumatoid factor production in rats (162). AIL was 
also established in mice from CIA-susceptible DBA/1J and CIA-resistant FVB/N mouse 
strains that share the H2q haplotype. This AIL has been used for high-resolution fine 
mapping of QTLs controlling the onset, severity, T cell subset and antibody response of 
CIA (163). 
2.2.2 From QTLs to genes: congenic strains and positional cloning 
The second stage in gene identification is more laborious and takes longer time involving 
genotyping many generations and disease-phenotyping many rat strains. Once a QTL is 
identified, the goal is to firstly confirm the QTL effect in a congenic fragment, and 
secondly minimise the fragment to arrive at a region as small as possible, ideally containing 
only one (or a few) genes. Once this is achieved, further experiments can be performed to 
identify and analyse the functional roles of the disease causative gene(s). 
Congenic strains are generated by transferring a specific chromosomal region from a donor 
strain to a recipient inbred strain. Initially, the donor strain is crossed to the recipient strain. 
The goal is then to replace, through many generations of backcrosses to the recipient strain, 
the ‘contaminating’ donor alleles with recipient alleles, with the exception of the disease-
associated locus. Each backcross statistically reduces the ‘contaminating’ donor alleles by 
50% and theoretically after ten generations of backcrossing, the resulting new strain will 
consist of ~99.8% recipient strain and can be considered a congenic strain. Since each 
generation takes about 3 months, this process of backcrossing can take almost 3 years. This 
process can however be shortened by the generation of ‘speed congenics’ so that only five 
to six, instead of ten, generations of backcrossing are needed. This is achieved by 
performing genome-wide analysis of genetic polymorphisms at each generation. Animals 
for the next generation of breeding are then selected by not only the presence of donor 
allele at the locus of interest but also by the absence of ‘contaminating’ donor alleles in 
other parts of the genome.  
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Once a congenic strain is established and the QTL disease phenotype is reproduced in the 
congenic strain, the next step is to minimize the size of the congenic fragment. Initially, 
congenic fragments are usually large stretching many megabases with tens or hundreds of 
genes and it is thus very difficult to pinpoint the causative genes. The congenic strain is 
screened for genetic recombinations. When a recombination is identified, smaller 
subcongenic strain can be generated and tested for the disease phenotypes. Once a smaller 
recombinant which still possesses the disease phenotype is identified, then we search for 
even smaller recombinants with fewer genes yet still possessing the disease phenotype. 
Finally, when the locus is reduced to the smallest size that is difficult to dissect any further 
by genetic recombination, in depth analysis of the locus is then performed to identify the 
disease causative gene(s) (if the locus consists of many genes) and to elucidate pathogenic 
mechanisms of the disease gene. This analysis may involve extensive DNA sequencing of 
the locus to identify all the genetic polymorphisms, expression analysis of the genes in the 
region to identify differentially-expressed genes, protein analysis by methods such as 
western blot or mass spectrometry, or functional assays such as promoter assays or 
transfection experiments. To obtain conclusive evidence of the functional consequence of 
any particular polymorphism, additional genetic manipulation of the candidate genes, such 
as transgenic or knockout technology, is often required.  
2.2.3 Positional cloned genes 
Over the past 20 or so years, different research groups have identified over 100 QTLs that 
contribute to various arthritis traits in rats (www.rgd.mcw.edu). These QTLs regulating 
different disease phenotypes including disease onset, severity and autoantibody production 
were identified in different models (CIA, PIA, OIA, AIA). Among all these QTLs, five 
underlying causative genes or gene clusters have so far been successfully positionally 
cloned (164). These genes are RT1-B, Ltab-Ncr3, APLEC, Ncf1 and Igl. The genes APLEC, 
Ncf1 and Igl will be briefly discussed in this section and studies on RT1-B and Ltab-Ncr3 
will be discussed in further depth in section 4. 
Ncf1 
Ncf1 (neutrophil cytosolic factor 1) is the first positionally-cloned gene in rats (165). It is a 
gene that is located inside the locus Pia4, which emerges in an F2 intercross between the 
arthritis-susceptible DA and the arthritis-resistant E3 (152, 165). Pia4 regulates not only 
PIA, but also CIA, OIA, and HXIA. In order to identify the gene underlying the Pia4 
disease association, congenic strains with Pia4 from the E3 genetic background 
introgressed into the DA background were generated and tested for arthritis. By testing 
different congenic strains that covered different parts of the Pia4 locus, the associated 
region was gradually narrowed to 300-kb interval that is associated to arthritis protection 
(165). This 300-kb interval contained only two genes, Ncf1 and Gtf2i (general transcription 
factor Iii). Only Ncf1 is polymorphic with two non-synonymous single nucleotide 
polymorphisms (SNPs) at positions 106 and 153 of the protein and it was later shown that 
position 153 mediates arthritis resistance in rats (166). As part of the NADPH complex, 
NCF1 is involved in the production of reactive oxygen species (ROS) (167). The finding 
that arthritis-protective congenic rat showed an increased ROS production (165) was 
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surprising since the release of ROS is widely believed to be proinflammatory. This 
discovery in rats was further supported by the findings that a mouse with spontaneous 
mutation in the Ncf1 gene produces undetectable ROS and develops enhanced arthritis 
(168). In humans, the NCF1 region in human is more complicated, characterised by 
deletions, duplications and inversions (169). A case-control study showed that an increased 
copy number of NCF1 is associated with arthritis protection (170). The effect of Ncf1 is not 
arthritis-specific. For example, mutated Ncf1 has been associated with EAE (168), 
spontaneous development of lupus (171) and also increased severity in mouse model of 
psoriasis (172) and gout (173).  
APLEC 
In addition to the Pia4 locus, another PIA QTL that emerged from the F2 intercross was 
Pia7 located on chromosome 4 (152, 174), which was found to also regulate OIA (133), 
and CIA (175). The QTL effect was reproduced in congenic strains (126, 131, 146, 176) 
and was positionally mapped to a 544-kb interval with the APLEC (antigen-presenting 
lectin-like receptor gene complex) (148, 149). This complex consists of lectin-like receptor 
genes, including Mincle (macrophage-inducible C-type lectin), Mcl (macrophage C-type 
lectin), Dcar1 [dendritic cell (DC) activating receptor 1], Dcir1-4 (DC immunoreceptor 1-
4) and the Dectin pseudogene Dectin2p (DC-associated C-type lectin 2 pseudogene). Six of 
the seven genes in this complex were found to be differentially expressed in the lymph node 
and/or carry a missense or nonsense mutation in DA rats (148). It remains to be shown 
whether the effect of the APLEC locus is due to a haplotype with contributions coming 
from multiple interacting genetic polymorphisms, or is due to polymorphism(s) in a single 
gene exerting the QTL effect. In addition to arthritis, the APLEC polymorphisms also have 
other effects, including disease susceptibility and severity, and antibody response of MOG-
EAE (177); and motor neuron survival after traumatic nerve root injury (178). In the 
mouse, APLEC has also been associated with arthritis (179), experimental colitis (180, 
181), EAE as well as response to infection (182).  
Igl 
Rheumatoid factors were the first autoantibodies identified in RA and can be detected in 
serum long before disease onset (7). However, very little is known about the genetic control 
of RFs. In rats, linkage analysis on a (DAxE3) F2 cohort identified three genetic loci that 
regulate RF production, namely Rf1, Rf2 and Rf3 (183). To study the effect of one of these 
three genetic loci, Rf1, a 6.7-Mb congenic strain was generated by introgressing Rf1 from 
E3 onto DA background. However, it was found that this 6.7-Mb region undergoes little 
recombination and it is thus difficult to further positionally identify the underlying 
causative gene simply by generating smaller subcongenic fragments (162). In order to 
overcome this difficulty, the advanced intercross line (AIL) generated between GK and 
F344 rat strains was used, genotyped and studied for RF levels. Combining the data from 
both the congenic and AIL crosses, we concluded that the Igl locus is linked to the RF 
production (162). In addition, the congenic rat developed more severe ovalbumin-induced 
airway inflammation, a model of allergic bronchitis or asthma (162). 
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2.3 Advantages and limitations of animal models and the approach of linkage analysis 
and congenic strains 
In order to advance our knowledge of rheumatoid arthritis, animal model is essential for a 
better understanding into the pathogenesis of the disease. This thesis describes how we use 
animal models to overcome limitations involved in human genetic studies to identify novel 
disease genes and to discover previously unknown disease mechanisms.  
The main advantage of using experimental disease models is the possibility to perform in 
vivo functional studies in well-controlled genetic and environmental settings, which is not 
possible in humans. In particular, the rat provides a unique opportunity to study arthritis 
induced by oil adjuvants, which is one of the environmental risk factors of RA (10) (section 
1.6). PIA is therefore an excellent model for studying the effect of adjuvants. PIA is highly 
reproducible with almost 100% incidence and induces a T-cell mediated, chronic relapsing 
disease course that closely mimics RA (116). 
The possibility to isolate congenic fragments on a fixed genetic background allows us to 
discover natural genetic variants of importance. For example, the NCF1 gene is usually not 
studied in human GWAS as a result of the complexity known in the human NCF1 region 
but was discovered in congenic rat analysis to have an important role in arthritis (165, 170). 
Once a disease gene is identified, deep analysis of the pathological roles of the gene can 
then be performed using the congenic strain. For example, the association of the arthritis-
protective DA.Ncf1E3 congenic rats with increased ROS production suggests an unexpected, 
protective role of ROS in autoimmunity. In addition, since many autoimmunity loci 
associate with multiple autoimmune diseases (184), congenic strains are highly useful to 
investigate the contributions of RA-associated genes to other autoimmune diseases. For 
example, APLEC polymorphisms was shown to regulate not only arthritis but also EAE 
(177); and Igl regulates ovalbumin-induced airway inflammation (162).  
However, it is also important to consider the differences between experimental arthritis and 
RA in humans when interpreting findings from animal models. Firstly, disease induction 
differs between experimental arthritis and RA. Experimental arthritis is induced by 
intradermal injection at the base of the tail with relatively well-defined agents, such as 
hydrocarbon adjuvants and/or a particular antigen, such as type II collagen. The disease 
trigger in humans is not identified but could possibly include airborne pollutants, food, 
cosmetics and so on. In humans, the disease is also most likely induced differently from 
rats. Different administration routes are known to lead to different disease outcomes in rats 
(116) and experimental arthritis models are likely only reflecting specific types of RA 
mechanisms, depending on the immunisation agents. This can be useful to investigate a 
particular type of RA mechanism, but the disease course in a particular model might not 
mirror the complex disease course in humans. It is also important to consider any genetic 
differences between humans and rats. For instance, in the rat genome, there is only one 
Ncf1 gene. In the human genome, there are several identical copies of NCF1 due to 
segmental duplications (185), and an increased copy number of NCF1 has been associated 
with lower susceptibility to RA in humans (170).  
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There are also drawbacks and limitations to use the linkage analysis and congenic approach 
to study disease association. Firstly, linkage analysis and congenic approach is performed 
in inbred strains and thus the ability to identify QTLs entirely depends on the allelic 
variants present in the genomes used. Secondly, positionally identifying a disease gene by 
isolating and narrowing down putative loci in congenic strains can take many years and 
requires a lot of animal breeding and screening. Thirdly, the success of positional cloning 
depends on identifying genetic recombinations. Both recombination-rich hotspots and 
coldspots exist in genomes (186) and thus some linked regions can be extremely difficult to 
split by recombinations. Transgenic and knockout technologies are attractive alternatives to 
study the functions of candidate genes, and new advances have enabled scientists to modify 
genes of any species, including rats. It is however important to note all genetic 
modifications are vulnerable to artefacts and could lead to different phenotypic outcomes 
(168, 187, 188). This could be due to regions flanking the targeted gene remaining of donor 
origin despite many generations of backcrossing to the host strain (189). It is also 
noteworthy that while targeted mutagenesis can be very useful for investigating specific 
hypothesis, it does not fully explain variation in complex traits. It has been suggested that 
single variants do not always entirely explain the genetic signals at a QTL and there can be 
multiple causal variants within a single QTL that contribute to the observed phenotypes 
(154). Even though positional cloning and functional assessment of genes in animal models 
is both time-consuming and expensive, it is more cost-effective and offers more functional 
insights than human genetic studies, for example, starting from large-scale GWAS.  
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3. MAJOR HISTOCOMPATIBILITY COMPLEX AND 
AUTOIMMUNE ARTHRITIS 
 
Figure 2: A comparison between the genetic organisation of the human (HLA), mouse (H2) 
and rat (RT1) major histocompatibility complex.  
The ~4-Mb major histocompatibility complex (MHC) plays a key role in regulating 
immune response and is associated with susceptibility to different autoimmune and 
infectious diseases. The MHC region is located on chromosome 6 in humans, chromosome 
17 in mice and chromosome 20 in rats (Figure 2). The MHC can be largely divided into 
three regions, the class I (MHC-I), II (MHC-II) and III (MHC-III) regions. The MHC-I and 
MHC-II regions contain genes encoding highly polymorphic MHC-I and MHC-II 
polypeptides that are involved in presentation of antigenic peptides to T cells. In humans, 
the MHC-I region includes genes such as HLA-A, HLA-B and HLA-C, and the MHC-II 
region includes genes such as HLA-DP, HLA-DQ, and HLA-DR. The class Ia molecules 
present intracellular antigens to cytotoxic CD8+ T cells; whereas the class II molecules 
present antigens to CD4+ T cells. The function of the class Ib genes are not clear. The MHC 
class III region contains an array of genes encoding mostly immune-related proteins, 
including the tumour necrosis factor (TNF) superfamily, component of the complement 
cascade, and molecular chaperones such as heat-shock proteins.  
The MHC is the most gene-dense region in the genome. The MHC region contains ~230 
known genes and pseudogenes. The average gene density of the MHC region is 
approximately 1 gene per 16 kb, which is higher than the genome average of 1 gene per 60 
kb (190). The MHC region is extremely polymorphic (191), in particular for MHC-I and 
MHC-II molecules, and this is thought to be driven by the rapidly-changing needs of our 
immune system. Not surprisingly, the MHC region is associated with more diseases than 
any other regions in the human genomes and is linked to nearly all autoimmune diseases 
(192). Nevertheless, the functions of many of the genes in the MHC region are still 
unknown and it is estimated about 40% of the expressed genes have immune functions 
(190). Clustering of genes with similar immune functions is quite common in the MHC 
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region, for instance, in the classical MHC-II region where almost all the genes are immune-
related. Proximity of genes might reflect the coevolution of functions or coexpression of 
transcripts. There is also an interesting difference in the proportion of pseudogenes in 
different MHC regions. For instance, there are very few pseudogenes in the MHC-III 
region; whereas there are many pseudogenes in the MHC-I and MHC-II region. It is also 
found that alternative splicing is enriched among MHC genes compared to non-MHC genes 
and alternative splicing seems to be haplotype-specific (193). 
3.1 MHC class I 
The structure of the MHC-I region differs quite significantly between rat, mouse and 
human. Firstly, the rodent MHCs are unique in the presence of centromeric MHC-I gene 
cluster proximal to MHC-II regions, called RT1-A in rats and H2-K in mice (Figure 2). 
Secondly, MHC-I genes in rats and mice also vary in copy numbers between different 
haplotypes (194). Thirdly, both rat and mouse MHC lack the MIC genes (MICA to MICG) 
present in human MHC-I. Lastly, the rat MHC-I RT1-A and RT1-C/E regions are distinctly 
different from mouse in various genomic features, such as gene numbers and organisation, 
suggesting independent evolution of the region after speciation of mouse and rat 16 to 23 
million years ago (194). Telomeric to MHC-II and MHC-III, there are clusters of non-
classical MHC-I genes which can be found in both humans and rodents. MHC-I molecule 
consists of three domains, namely α1, α2, and α3, and a non-MHC molecule β2 
microglobulin unit is attached to the α1 domain. The transmembrane domain α3 anchors the 
MHC class I molecule to the cell membrane and the peptide-binding groove is located on 
the α1/α2 heterodimer. In humans, HLA-A, HLA-B and HLA-C encode the MHC class I 
heavy chains. Polymorphisms of the MHC-I proteins result in unique peptides binding to 
the peptide binding grooves of each protein. 
MHC-I molecules present peptides of cytosolic origin. First, antigens are degraded by the 
proteasome. The resulting peptides are then transported from the cytosol to the endoplasmic 
reticulum (ER) via the transporter associated with antigen presentation (TAP) (195). Inside 
the ER, TAP forms the peptide loading complex (PLC) consisting of MHC-I molecules, 
ERp57, calreticulin and tapasin. Although peptides are trimmed before entering ER, 
peptides may be trimmed further by ER aminopeptidase associated with antigen processing 
(ERAAP) before binding with MHC-I (196). Peptide-MHC class I complexes are then 
transported to the plasma membrane via the Golgi for antigen presentation to CD8+ T cells. 
In the ER, ER-associated protein degradation (ERAD) system transports unbound peptides 
back to the cytosol for further trimming or destruction by peptidases and the proteasome 
(197).  
3.2 MHC class II 
The MHC-II genes encode a number of peptide-binding proteins and proteins involved in 
the process of antigen loading. The organisation of the MHC-II region, both the gene 
content and order, are generally well-conserved in rats, mice and humans. Similar to MHC-
I, there are duplicated modules in MHC-II. Among the 19 MHC-II genes in humans, 8 are 
pseudogenes. The number of pseudogenes differs between haplotypes (198). MHC-II itself 
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is a heterodimer consisting of an α chain and a β chain, each with two domains, α1 and α2, 
β1 and β2. The transmembrane domain α2 and β2 anchor the MHC-II molecule to the cell 
membrane and the peptide-binding groove is formed on α1 and β1 domains. The human 
MHC-II locus encodes three classical MHC-II proteins on the cell surface: HLA-DR, HLA-
DQ and HLA-DP (mouse expresses I-A and I-E, rat expresses RT1-B and RT1-D). The 
MHC-II molecules are mainly constitutively expressed by professional APCs, such as 
dendritic cells, macrophages and B cells; and these MHC-II molecules present peptides to 
CD4+ T cells. Polymorphic residues are found mostly in the β chains of HLA-DR, HLA-
DQ and HLA-DP. The HLA-DR α chain is invariant, and the α chains of HLA-DQ and 
HLA-DP are partly polymorphic. The amino acid variants are mostly located in and around 
the peptide-binding groove of these MHC-II molecules, resulting in different peptides 
associated with different MHC-II alleles. Unlike MHC-I, MHC-II peptide binding groove is 
more open so that peptides can extend out of the MHC-II structure. This means MHC-II 
can bind to both longer peptides and also unfolded and native proteins (199).  
Different from the ubiquitously-expressed MHC-I molecules, MHC-II molecules are 
expressed by professional APCs, such as dendritic cells, macrophages and B cells. In the 
ER, the MHC class II αβ dimers associate with the invariant chain (Ii) (200, 201). The Ii–
MHC-II heterotrimers are then transported through the Golgi to the plasma membrane, 
where the heterotrimers are internalised by clathrin-mediated endocytosis and transported 
to antigen-processing compartments termed MHC class II compartments (MIICs). Here, Ii 
is degraded by resident protease such as cathepsin S and cathepsin L in the MIIC (202), 
leaving a residual class II-associated Ii peptide (CLIP) in the binding groove of the MHC-II 
dimer (203). The CLIP competes with other peptides in the MIIC to exclude low affinity, 
non-specific peptides from the binding groove of the MHC-II. In the MIIC, the HLA-DM 
regulate the exchange of the CLIP peptide for a specific peptide (204, 205) and the activity 
of HLA-DM is modulated by HLA-DO via an unknown mechanism. MHC class II 
molecules are then transported to the plasma membrane for peptide presentation to CD4+ T 
cells. 
3.3 MHC class III 
The organisation of the MHC-III region is also conserved between rats, mice and humans 
with a few exceptions. First, at the centromeric end of the MHC-III region, there is a 
rodent-specific expansion of the butyrophilin-like (Btnl) genes. These genes expand 
independently (194), suggesting rapid evolution of these genes. Second, there is a rat-
specific modular duplication of the C4 complement gene and adjacent regions that is not 
found in humans and mice. The MHC-III region is the most gene-dense in the human 
genome, containing ~60 genes in ~700 kb with an average gene size of ~8.5 kb, compared 
to genome average of 27-45 kb (35, 206, 207). MHC-III region is very compact. While the 
average number of exons per gene (~11) and the size of the mRNA (~1.7 kb) is similar to 
the genome average, the average size of the MHC-III genes is significantly smaller than the 
genome average (MHC-III: 8.5 kb in humans, 7.7 kb in mice versus human genome 
average: >27 kb) (35, 207). MHC-III genes have shorter introns (MHC-III: 0.63 kb in 
humans, 0.58 kb in mice versus genome average: 4.7 kb in humans, 3.9 kb in mice) and 
shorter intergenic distances in MHC-III than genome average (35, 208). Several MHC-III 
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genes undergo extensive alternative splicing, for example LST1 and APOM. The LST1 gene 
is known to have at least 17 splice variants encoding for transmembrane as well as soluble 
LST1 in humans (209). Unlike the highly polymorphic MHC-I and MHC-II regions, the 
sequence variation of the MHC-III is actually comparable to the genome average (35). The 
MHC-III proteins have functions different from MHC-I and MHC-II and play wide-ranging 
roles such as acting as component of the complement system, cytokines, heat shock 
proteins and so on. Several of the MHC-III proteins that are more relevant to this thesis are 
briefly discussed here.  
TNF is one of the most well-known MHC-III protein and was first discovered as a factor in 
serum in response to endotoxin that caused necrosis when injected into tumours (210). 
Mainly produced by monocytes and tissue macrophages, TNF plays a central role in 
triggering the inflammatory reactions of the innate immune system, such as inducing 
cytokine production and stimulating growth. TNF is initially produced as membrane-bound 
protein, and is released as a homotrimer upon cleavage by TNF-converting enzyme (TACE) 
and binds to one of the two receptors, TNFR1 or TNFR2. This initiates further signalling 
cascade leading to phosphorylation of NF-κB and activation of the p50-p65 subunit, which 
then increases transcription of other proinflammatory genes. Synthesis of TNF is tightly 
regulated because of its important proinflammatory functions.  
The lymphotoxin genes (LTα and LTβ) are located next to TNF in the MHC-III region in 
the genome. Similar to TNF, LTα also binds to TNFR1 and TNFR2 as a homotrimer, and in 
addition, binds to the herpes virus entry mediator (HVEM). Furthermore, LTα forms a 
heterotrimer with LTβ and binds to the LTβR. Both LT and TNF are proinflammatory (211, 
212), although it is generally believed that LT is not as strong and important as TNF. LT is 
essential for the development of secondary lymphoid organ, since LTα knockout mice have 
no lymph nodes, no Peyer’s patches and highly disorganised spleens (213, 214). LTβ-
deficient mice have similar but less drastic phenotype, and unlike LTα-deficient mice, 
retain cervical and mesenteric lymph nodes (215), which suggests a unique signalling role 
for LTα3. Thus, LT is important in the maintenance of lymphoid organs through its 
production by B cells, T cells and DCs.  
The biological functions of LST1 proteins are largely unclear and it is also not known how 
many of the splice variants are translated into proteins. One of the transmembrane variants 
LST1/C have been shown to exhibit inhibitory effect on lymphocyte proliferation (209). 
Overexpression of the isoform LST1/A in human cell lines was shown to induce the 
formation of filopodia and microspikes at the cell surface (216) and was recently suggested 
to play a negative regulatory role on signal propagation in myeloid cells (217). 
3.4 Regulation of MHC class II expression by CIITA  
MHC-II expression is tightly regulated at the level of transcription by MHC class II 
transactivator (CIITA). CIITA is the master regulator of MHC class II expression, and is 
recruited by the enhanceosome to the X1, X2 and Y box elements in the MHC-II genes 
(218). CIITA then coordinates the recruitment of other factors involved in chromatin 
modification and remodelling such as CREB-binding protein (CBP) and p300. CIITA also 
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coordinates the recruitment of factors for transcription initiation and elongation, such as 
transcription factor IIB (TFIIB) and TFIID (218). There are four CIITA isoforms in humans 
(pI, pII, pIII and pIV) (219) and three Ct2a isoforms in the mouse and rat (pI, pIII and pIV), 
each with a cell-specific promoter (type I, III and IV). The type I promoter drives the 
CIITA expression by conventional dendritic cells and interferon-γ activated macrophages. 
The type III promoter drives CIITA expression by B cells and activated human T cells, as 
well as plasmacytoid dendritic cells. The type IV promoter is important for CIITA 
expression by cortical thymic epithelial cells and in cells of non-haematopoietic origin such 
as fibroblasts upon interferon-γ induction (220, 221). 
3.5 MHC class II and autoimmune arthritis 
Since the identification of the link between HLA and RA half a century ago (34) which was 
further defined by the ‘shared epitope hypothesis’ (36) (as described in section 1.5), many 
groups have examined the association between SE and RA in different cohorts and different 
subgroups of RA. SE is significantly associated with increased risk of developing RA, 
especially for ACPA-positive RA (222–228). However, it is important also to note that not 
every RA patient carries SE alleles and SE alleles do not necessarily lead to development of 
RA. This suggests that genes other than HLA-DRB1 also contribute to disease aetiology. 
Different studies have detected RA association signals from other MHC regions, from both 
within the class II region (DPB1, DOB, DQA, DQB), as well as class I region (HLA-C, 
HLA-B) and class III region. (229–232). Recent meta-analyses confirmed and refined the 
SE to positions 71 and 74 and extends to position 11 (and 13) in individuals with ACPA-
positive RA (3). These studies identified disease association in HLA-A (position 77), HLA-
B (position 9) and HLA-DPB1 (position 9) (3, 4). Interestingly, the strongest association 
signal was detected at HLA-DRB1 amino acid position 11 (or 13), which is located outside 
the previously described shared-epitope region but within the antigen-binding groove. Only 
after controlling for position 11 in HLA-DRB1, positions 71 and 74 in HLA-DRB1 and 
other association signals were detected by stepwise conditional analyses. It is not clear 
however whether position 11 or 13 is the main driving influence due to the physical 
proximity of the two positions. Similar disease association signals were detected in ACPA-
positive RA cases among Chinese and Korean populations (233). The exact functional roles 
of the amino acid variants in an MHC-II molecule on disease development remains to be 
clarified, although the location of the amino acid variants within the peptide-binding 
grooves suggests that these polymorphisms might have an impact on antigenic presentation 
to T cells, either during early thymic development or during peripheral immune responses.  
In rats, the strong genetic association of MHC genes on chromosome 20 with the 
development of experimental arthritis has been shown in different linkage analyses. In the 
F2 intercross between disease-susceptible DA and relatively resistant F344 rat strains, it 
was found that the MHC locus is associated with both CIA (denoted as Cia1) (127) and 
Mbt-AIA (denoted as Aia1) (140). A backcross between the disease-susceptible DA and 
disease-resistant E3 rat strains similarly showed that the MHC regulates PIA (denoted as 
Pia1) and CIA (126, 131). Congenic rat strains differing only in the MHC locus similarly 
demonstrated that MHC regulates different models of experimental arthritis, including CIA, 
PIA and OIA (126, 131, 145, 234–236). The importance of MHC is also shown in analysis 
 24 
of congenic mice strains that only strains expressing certain MHC class II such as Aq but 
not Ab (expressed by the C57BL/6) conferred susceptibility to arthritis (237–239). This 
thesis describes how we utilised a panel of MHC-II congenic rat strains to study the 
pathogenic mechanisms of the MHC-II in experimental arthritis. 
3.6 MHC class III and autoimmune arthritis 
In addition to the MHC-II genetic contributions to RA, multiple studies have suggested 
independent genetic association of MHC-III genes with RA development (232, 240–247). 
Given the important immunoregulatory roles of the MHC-III proteins as discussed in 
section 3.3, some of them have also been described as candidate genes for RA. The most 
well-known candidate gene in the region is TNF (247). Different SNPs in the TNF gene (for 
instance, at positions -308, -238, +489) have been investigated for disease association and a 
recent meta-analysis showed that TNF-308 is associated with joint damage in patients with 
RA (247). Both monoclonal anti-TNF antibody and TNFR fusion proteins have been 
developed to target TNF for RA treatment (248, 249). Other candidate genes include LTA 
(lymphotoxin α) (250, 251), LTB (lymphotoxin β), LST1 (leukocyte specific transcript 1), 
NCR3 (natural cytotoxicity triggering receptor 3) (252), and AIF1 (allograft inflammatory 
factor 1) (241, 246). The importance of lymphotoxins in experimental arthritis was shown 
when it was found that blocking LTB resulted in altered development of CIA in mice (253, 
254). A monoclonal antibody Pateclizumab targeting LTα3 and LTα1β2 has been developed 
and is under initial clinical trial in RA patients (255). In addition, significant elevation in 
expression of LTB, NCR3 and an isoform of LST1 have been found in blood and synovium 
from RA patients (250, 252) and increased expression of AIF1 was found in RA 
mononuclear cells (241, 246). However, the high gene density, extreme polymorphism and 
the strong LD across the MHC have made this region very difficult to investigate for 
disease association (256, 257) and so far evidence showing the direct contribution of 
genetic polymorphism in the MHC-III in pathogenesis of RA is lacking. This thesis 
describes how we made use of congenic rat strains isolated in the MHC-III region to show 
natural genetic polymorphisms in the MHC-III regulates experimental arthritis. 
3.7 CIITA and autoimmune arthritis 
Given the known strong link between MHC-II and development of RA, the master 
regulator of MHC-II genes, CIITA, has also been studied to access the impact of 
quantitative difference of MHC-II expression on arthritis development in both humans and 
rodents. It was first identified in a genetic analysis of an advanced intercross line in rats that 
polymorphisms in the 5’ flanking region of C2ta explain strain-dependent differences in 
expression of MHC-II molecules (258). Congenic rat strain with the C2ta polymorphisms 
not only had a lower MHC-II expression but also developed milder experimental 
autoimmune encephalomyelitis (EAE), a chronic relapsing model of MS (259). The 
experimental findings in rats led to further investigation of C2TA in humans and a single 
nucleotide polymorphism in the 5’ flanking region of type III promoter of CIITA has 
associated with the risk of developing MS, RA and myocardial infarction (258). CIITA 
disease association has since then been shown in different patient cohorts, in not only RA 
(260, 261) and MS (262, 263), but also T1D (264), celiac disease (265) and systemic lupus 
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erythematosus (SLE) (266, 267). Nevertheless, this disease association could not be 
reproduced in some populations (268–270). Several SNPs located in different parts of 
CIITA have been studied for disease association, including -168A/G polymorphism, 
rs3087456 in the type III promoter of CIITA, an intronic SNP rs8048002, and rs4774 which 
is a missense mutation resulting in an amino acid change from glycine to alanine (258, 260, 
263). The rs3087456 is the most investigated for disease association in humans. This thesis 
describes how we used a C2ta congenic mouse strain to study the effect of natural genetic 
variants in the type I promoter of C2ta on MHC-II expression and the subsequent 
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4. PRESENT INVESTIGATIONS 
Figure 3: Overview of the main MHC congenic recombinant strains discussed in this thesis. 
Studies I and II describe the regulation of arthritis by the MHC-II RT1-B genes (shaded in 
brown). Studies IV and V describe the regulation of arthritis by the MHC-III Ltab-Ncr3 
genes (shaded in brown). Study III describes how Tap2 (indicated by an arrow) in MHC-II 




4.1 Study I 
Positional Identification of RT1-B (HLA-DQ) as Susceptibility Locus for Autoimmune 
Arthritis 
Since the strong link between MHC-II and RA was known more than 40 years ago, little is 
known about the precise underlying causative polymorphisms. Recent results from genome-
wide association studies refined the association to six different amino acids in HLA-DRB1, 
HLA-A, HLA-B and HLA-DPB1 (3, 4). The strong genetic association of MHC genes in 
experimental arthritis was also shown in multiple linkage analyses (127, 131, 140, 152) and 
reproduced in congenic rat strains (131, 145, 236). 
In this study, we examined the genetic association of the MHC-II genes using a panel of 
congenic strains mapped to the MHC-II region. Three congenic strains were generated by 
introgressing different inbred rat strains, namely KHW (RT1h haplotype), AS2 (RT1f) and 
E3 (RT1u), onto a DA (RT1av1) background. We induced pristane-induced arthritis (PIA) in 
these rats and assessed their arthritis development. Two of these congenic strains, namely 
DA.1HR61 (RT1h) and DA.1UR10 (RT1u) developed milder acute PIA than wt DA 
controls (RT1av1); whereas DA.1FR9 (RT1f) developed enhanced acute PIA. In order to 
pinpoint the underlying causative genes within the 0.2-Mb mapped QTL (called Tcs2), we 
examined the coding variants of the genes within Tcs2 and correlated the coding variants 
with disease severity. We identified that RT1-Ba and RT1-Bb, the rat orthologues of the 
HLA genes, HLA-DQA and HLA-DQB, to be the main candidate genes determining arthritis 
susceptibility. Blocking RT1-B with an antibody against RT1-B resulted in significantly 
milder PIA in all strains, further supporting a role of RT1-B in PIA. We found that the RT1-
B was differentially expressed on both macrophages and dendritic cells. However, the 
variation in expression levels of RT1-B does not explain the difference in arthritis severity 
between the strains. We then compared the peptide repertoire of RT1-B between different 
strains; and showed that the peptide repertoire of RT1-B differs substantially between 
strains. The binding pockets of the arthritis-protective congenic strains DA.1HR61 and 
DA.1UR10 prefer binding with glutamic acid; whereas arthritis-promoting DA.1FR9 binds 
preferentially to hydrophobic amino acids. The peptide binding data is further supported by 
the fact that arthritis-protective strains share amino acid variants in the peptide-binding 
RT1-B P1 pocket.  
In summary, we positionally identified a 0.2-Mb interval in the rat MHC-II region that 
regulates the onset and severity of PIA; and our genetic and functional findings on the four 
MHC-II haplotypes provide strong evidence that amino acid variations in RT1-B may 
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4.2 Study II 
Class II Major Histocompatibility Complex–Associated Response to Type XI Collagen 
Regulates the Development of Chronic Arthritis in Rats 
The aims of this study were to characterise the immune response at different stages of 
pristane-induced arthritis (PIA) in rats to joint-specific cartilage antigens, such as type II 
collagen (CII) and type XI collagen (CXI), and to identify the underlying genetic 
association in the MHC-II region. This is achieved by generating and assessing arthritis 
development in recombinant congenic rat strains (haplotype RT1f) covering different parts 
of the MHC region.  
We first assessed the susceptibility to CII-induced arthritis (CIIIA) and CXI-induced 
arthritis (CXIIA) in congenic rat strains DA.1FR8, DA.1FR9 and DA.1FR10, and DA 
control rats. For CIIIA, while DA.1FR9 rats developed milder arthritis, DA.1FR8, 
DA.1FR10 and DA rats developed severe arthritis. This shows that the ~0.2-Mb MHC-II 
region contributes to susceptibility to CIIIA. Almost the opposite occurs in CXIIA. While 
DA.1FR9 rats developed severe CXIIA. DA.1FR8, DA.1FR10 and DA rats developed mild 
arthritis. Taken together, susceptibility to CIIIA and CXIIA was linked to haplotypes RT1av1 
and RT1f, respectively. Having mapped the collagen response to the ~0.2-Mb MHC-II 
region, we next evaluated T cell and antibody responses to CII and CXI at different stages 
of PIA. After pristane injection, both DA.1F (RT1f) and DA (RT1av1) developed T cell and 
antibody responses to CII, but not CXI. However, in chronic PIA, rats developed stronger 
reactivity to CXI, not CII, and such reactivity is restricted to RT1f haplotype. Genetic 
sequence analysis of the four MHC class II genes, RT1-Ba, RT1-Bb, RT1-Da and RT1-Db1, 
found a number of coding variants in the peptide-binding domains of RT1-Ba but no 
polymorphisms in RT1-D. This strongly supports an association of RT1-B genes with CXI 
immunity. In order to assess whether the collagen reactivities seen in PIA is also found in 
RA, we determined the proportion of RA patients with antibody responses to CII and CXI. 
We showed that 12% of RA patients developed specific IgG response to CXI, 6% to CII 
and 6% to both.  
In summary, this study demonstrates the development of MHC-II-associated reactivity 
towards CXI in chronic arthritis suggesting a role of CXI autoreactivity in the development 





4.3 Study III 
Natural Polymorphisms in Tap2 Influence Negative Selection and CD4∶CD8 Lineage 
Commitment in the Rat 
This study aims to address the impact of natural genetic polymorphisms in both MHC-I and 
MHC-II regions on MHC expression and CD4:CD8 lineage commitment using both the 
outbred heterogeneous stock (HS) rats and inbred recombinant congenic strains generated 
in the MHC region.  
Using the HS rats, we mapped genome-wide QTLs which are associated with variation in 
the MHC-I and MHC-II protein expression and the CD4:CD8 T cell ratio. A total of ten 
QTLs were identified across the genome. Among these QTLs, we identified a region 
spanning 4.1-9.7 Mb on chromosome 20. Such region overlaps with the MHC region that 
regulates both CD4:CD8 T cell ratio and MHC expression.  
In order to refine this region that contributes to this phenotypic variation, we generated a 
panel of MHC-recombinant congenic strains derived from AS2 (RT1f), KHW (RT1h), E3 
(RT1u) and BI (RT1i) on a DA (RT1av1) background. The congenic panel includes congenic 
strains mapped to MHC-I (Tcs1) and MHC-II (Tcs2) regions. Phenotyping of the MHC-I 
and MHC-II congenic strains revealed that 282-kb Tcs1 regulates MHC-I expression and 
CD4:CD8 T cell ratio; and the 206-kb Tcs2 regulates both MHC-I and MHC-II expression, 
and the ratio of CD4:CD8 T cells. The effect of Tcs2 on MHC-I expression and the T cell 
numbers was in fact due to interactions between Tcs1 and Tcs2; and we studied this 
interaction effect using congenic strains isolated in the MHC-I and MHC-II region made 
possible by recombinations occurring between Tcs1 and Tcs2. By correlating the sequence 
variants of the genes within Tcs2 with variation in MHC-I expression, we mapped the 
interaction effect to Tap 2 (transporter associated with antigen processing 2) in the MHC-II 
region and the classical MHC-I genes RT1-A in the MHC-I region. This study confirmed 
the previously known phenomenon, class I modification (cim), which reduced the 
expression of TAP-A linked RT1-A molecules if associated with TAP-B. In addition, this 
study identified a novel phenomenon which we named ‘inverse’ cim. Inverse cim reduced 
the expression of TAP-B linked RT1-A molecules when linked with TAP-A (Figure 4). 
Genetic variations in Tap2 have previously been shown to alter the peptide repertoire of 
MHC-I molecules which then influence the antigenicity of the MHC-I molecules (272, 
273). This study further shows that a restricted peptide repertoire on MHC-I molecules 
reduces negative selection of CD8 single-positive T cells in the thymus.  
In summary, we show how combination of a particular allelic variant of Tap2 and a 
particular allelic variant of RT1-A genes could influence negative selection and lineage 
commitment of T cells in rats. 
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Figure 4: Summary figure for class I modification (cim) and inverse cim. The classical cim 
reduced the expression of TAP-A linked RT1-A molecules if associated with TAP-B. The 






4.4 Study IV  
Conserved 33-kb haplotype in the MHC class III region regulates chronic arthritis 
Recent results from genome-wide association studies confirmed the association between 
classical MHC-II alleles and RA (3, 4). In addition, different studies have suggested that 
genes in the other parts of the MHC region, such as MHC-III, also contribute to arthritis 
development (232, 240–246), as discussed in section 3.6. However, this disease 
contribution has been difficult to show owing to the high gene density, extreme 
polymorphism and the strong linkage disequilibrium across the MHC (256). 
In study I, we showed that the RT-1B genes in MHC-II regulate the acute phase of pristane-
induced arthritis (PIA) (147). In this study, using MHC-III congenic strains, we showed 
that there is a second arthritis QTL in the non-classical MHC-Ib and/or the MHC-III region. 
By generating and disease-phenotyping a panel of ten subcongenic strains mapped to these 
regions, we further narrowed down this QTL to a 32.7-kb interval, denoted Ltab-Ncr3, in 
the telomeric end of the MHC-III region comprising five genes, Ltα, Tnf, Ltb, Lst1 and 
Ncr3. We showed that Ltab-Ncr3 determines not only the onset and severity, but also the 
chronicity of PIA. By performing the reciprocal adoptive transfer of in vivo pristane-primed 
T cells between the congenic and DA rats, we demonstrated that Ltab-Ncr3 regulates the 
priming but not the effector phase of arthritis.  
We found that the Ltab-Ncr3 region is rather resistant to recombinations, as evident from 
the absence of recombination in this region in over 8000 rats genotyped. SNPs information 
in the Ltab-Ncr3 region in non-related wild rats also supports the existence of a conserved 
haplotype in Ltab-Ncr3. Significant correlation in the expression of the Ltab-Ncr3 genes 
provides further support that interaction of these genes may be of importance in 
maintaining these genes clustered together as a conserved haplotype.  
By performing a number of in vitro and in vivo assays in the congenic and control rats, we 
showed that polymorphisms in Tnf do not contribute to the Ltab-Ncr3 haplotype effect. We 
assessed the level of expression of Ltab-Ncr3 genes in the arthritis-protective congenic 
DA.1HR56D (haplotype RT1h) and arthritis-prone control DA (RT1a); and also in other 
arthritis-prone congenic DA.1FR9 (RT1f) and DA.1UR2A (RT1u). We showed that higher 
Ltb and Ncr3 expression, lower Lst1 expression and the expression of a shorter isoform of 
Lst1 correlate with reduced arthritis severity (Figure 5). We examined the expression of 
LTB, LST1 and NCR3 genes in the whole blood from a cohort of 32 RA patients and 92 
healthy controls. Similar to the findings in the DA.1HR56D arthritis-protective congenic 
rats, patients with mild RA (DAS28 ≤ 3.2) also showed higher NCR3 expression and lower 
LST1 expression than patients with severe RA (DAS28 > 5.1).  
In summary, we identified a 33-kb conserved haplotype in the MHC-III that determines the 
onset, severity and chronicity of experimental arthritis; and haplotype-specific differences 
in both gene expression and alternative splicing correlates with arthritis development. 
These data demonstrate the importance of a conserved haplotype in the regulation of 
complex diseases such as arthritis. 
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Figure 5: Higher expression of Ltb and Ncr3, lower expression of Lst1, and the expression 





4.5 Study V 
MHC class III Ltab-Ncr3 haplotype regulates adjuvant-induced but not antigen-dependent 
autoimmunity. 
In study IV, we identified a 33-kb conserved haplotype Ltab-Ncr3 in the MHC-III that 
determines the onset, severity and chronicity of pristane-induced arthritis in rats. In study 
V, we evaluated this new genetic association with arthritis using different adjvuvant- and 
antigen-induced arthritis models. In addition, we used models for multiple sclerosis for 
comparison and dissect the MHC-III mediated mechanisms of importance for antibody and 
T cell responses to antigens.  
Using the MHC-III recombinant congenic strains, we showed that the Ltab-Ncr3 haplotype 
also regulates oil-induced arthritis (OIA), which is induced by the immunisation of 
incomplete Freund’s adjuvant (IFA). Both macroscopic scoring and histology analysis 
showed that the MHC-III congenic rat strain DA.1HR56D developed milder OIA than DA 
controls. DA.1HR56D rats are similarly protected in arthritis models induced by other 
hydrocarbon oils, such as hexadecane, heptadecane, squalene and arlacel. Adoptive T-cell 
transfer experiment showed that this arthritis-protective effect operated during the priming 
of T cells. Interestingly, Ltab-Ncr3 did not regulate autoimmune diseases induced with 
tissue-derived antigens emulsified in IFA, such as collagen-induced arthritis (CIA) and 
myelin-oligodendrocyte-glycoprotein-(MOG-) induced experimental autoimmune 
encephalomyelitis (EAE). The Ltab-Ncr3 haplotype also showed no effect on antibody or T 
cell response to tissue antigens such as type II collagen. 
To date, all the positionally cloned arthritis genes in rats (section 2.2.3 and study I, II) have 
been shown to regulate both PIA (and OIA) and CIA. Ncf1 and APLEC were shown to 
regulate PIA, OIA and CIA (126, 149, 165); and RT1-B (128, 147) regulates both PIA and 
CIA. To our knowledge, the Ltab-Ncr3 haplotype is the first fine-mapped locus that 
regulates only oil adjuvant induced arthritis models. In contrast to the pronounced effect of 
Ltab-Ncr3 on the priming of arthritogenic T cells in the oil adjuvant models, there was no 
such effect in CIA model or antigen-specific in vitro restimulation assay. One likely 
explanation is that the nature of T cell activation as a result of adjuvants exposing 
endogenous antigen in vivo is different from the one caused by the immunodominant effect 
of an administered exogenous antigen. We previously showed that addition of an 
immunogenic cartilage protein, such as CII, to IFA leads to a qualitative different disease, 
compared to the disease induced by IFA alone (120). This is also supported by our 
unpublished observations that passive transfer of CIA by CII-reactive T cells is not as 
effective as adoptive transfer of oil adjuvant-primed T cells. All these data suggest that the 
mechanisms involved in the priming of T cells with no exogeneous antigen in OIA (which 
is regulated by Ltab-Ncr3) is different from T cells triggered after immunisation of 
immunodominant self antigens, such as CII in CIA or MOG in EAE (and is not regulated 
by Ltab-Ncr3).  
In summary, we showed that the 33-kb Ltab-Ncr3 haplotype in the MHC-III regulates oil 
adjuvant arthritis models but not autoimmune diseases triggered through immunisation with 
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tissue-derived antigens. The Ltab-Ncr3 haplotype seems to control mechanisms involved in 
the early events of an autoimmune response.  
 
Table 3: Summary of Ltab-Ncr3 regulation in different disease models. 
 
Disease models Ltab-Ncr3 disease phenotype 
Pristane-induced arthritis protective 
Oil-induced arthritis protective 
Hexadecane-induced arthritis protective 
Heptadecane-induced arthritis protective 
Squalene-induced arthritis protective 
Arlacel-induced arthritis protective 
Collagen-induced arthritis no effect 
rSCH-induced EAE no effect 






4.6 Study VI 
Effects of C2ta genetic polymorphisms on MHC class II expression and autoimmune 
diseases. 
MHC-II has been strongly associated with many autoimmune diseases including 
rheumatoid arthritis (RA) and multiple sclerosis (MS). Its expression is controlled by the 
class II transactivator (CIITA in human and C2TA in mouse), which is regulated by cell-
specific promoters (I, III, IV) as described in section 3.4. As discussed in section 3.7, 
genetic variation in CIITA has been linked to susceptibility to autoimmune disorders in 
humans (258, 260–267). In rodents, genetic variants in type III promoter of C2ta has been 
studied in a congenic setting and shown to be associated with experimental autoimmune 
encephalomyelitis (EAE), a chronic relapsing model of MS (259). Mice with a knockout in 
type IV promoter however developed collagen-induced arthritis (CIA) with comparable 
severity (274). 
In this study, we examined the effect of natural genetic variants in type I promoter of C2ta 
on MHC-II expression and autoimmune diseases. We achieved this by isolating a C2ta 
congenic fragment from the donor strain 129X1/SvJ onto a recipient C57BL/6N.Q 
background such that the congenic mice expressed the H2-Aq gene, facilitating the studies 
of the effect of C2ta in different experimental models of RA and MS (237, 275–277). We 
demonstrate that an allelic variant in the type I promoter of C2ta resulted in an increased 
expression of MHC-II on macrophages and conventional dendritic cells in both spleen and 
peripheral blood. MHC-II upregulation subsequently resulted in increased antigen 
presentation to T cells and increased T cell activation. This MHC-II expression difference 
however did not alter susceptibility of these mice to different experimental models of 
multiple sclerosis (MOG1-125 protein- and MOG79-96 peptide-induced EAE), or rheumatoid 
arthritis (CIA and human glucose-6-phosphate-isomerase325-339-peptide-induced arthritis). 
This is similar to the findings in study I that MHC-II expression difference on APCs did not 
correlate with the arthritis severity in the MHC-II congenic rat strains. Therefore, this and 
other studies (147, 259, 274) seem to suggest that quantitative difference in MHC-II plays a 
relatively minor role in the regulation of autoimmune diseases triggered by exogenous 
immunisation, such as EAE and CIA. 
In summary, we address the role of an allelic variant in the type I promoter of C2ta in 
MHC-II expression and autoimmune diseases; and demonstrate that upregulation of MHC-
II expression and subsequent antigen presentation as a result of C2ta polymorphisms does 
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